GlassScriptPhysician profile
Stephen Gutu
NPI 1528212594
$3,983.37
in general payments reported to CMS, 2019-2025
17 companies · $223 in 2025
The $223 reported for 2025 was less than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $203 · 2020: $112 · 2021: $142 · 2022: $1,008 · 2023: $312 · 2024: $1,985 · 2025: $223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,291 · Food and Beverage: $1,228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,290.94 |
| Food and Beverage | $1,228.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $2,432.05 | 2022-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Jazz Pharmaceuticals INC. | $392.34 | 2022-2025 | |
| Ucb, INC. | $188.73 | 2019-2025 | Fintepla, Briviact, Nayzilam |
| Neurelis, INC. | $164.27 | 2021-2025 | Valtoco |
| Supernus Pharmaceuticals, INC. | $150.31 | 2020-2022 | |
| Mallinckrodt Enterprises LLC | $125.00 | 2019 | |
| Sk Life Science, INC. | $92.44 | 2023-2024 | |
| Immedica Pharma US, INC. | $86.85 | 2023-2024 | |
| Greenwich Biosciences, INC. | $71.83 | 2020-2021 | |
| Acadia Pharmaceuticals INC | $71.37 | 2023-2025 | Daybue |
| Genzyme Corporation | $68.33 | 2021-2023 | |
| Sunovion Pharmaceuticals INC. | $31.25 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $30.12 | 2025 | Ajovy |
| Intrabio INC | $25.63 | 2025 | Aqneursa |
| Biogen, INC. | $21.52 | 2024 | Skyclarys |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomarin Pharmaceutical INC. | $15.90 | 2019 | |
| Zogenix INC. | $15.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Gutu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.